Design Therapeutics (DSGN) Expected to Announce Quarterly Earnings on Monday

Design Therapeutics (NASDAQ:DSGN) will likely be releasing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Design Therapeutics to post earnings of ($0.37) per share for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 11, 2026 at 12:30 PM ET.

Design Therapeutics Trading Down 2.2%

Shares of Design Therapeutics stock opened at $10.44 on Monday. The company has a fifty day simple moving average of $9.92 and a 200-day simple moving average of $8.02. The stock has a market cap of $594.66 million, a price-to-earnings ratio of -8.77 and a beta of 1.63. Design Therapeutics has a 12-month low of $2.60 and a 12-month high of $11.14.

Institutional Investors Weigh In On Design Therapeutics

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Design Therapeutics in the 4th quarter valued at $212,000. Invesco Ltd. boosted its holdings in shares of Design Therapeutics by 1,995.8% in the fourth quarter. Invesco Ltd. now owns 305,757 shares of the company’s stock valued at $2,868,000 after acquiring an additional 291,168 shares in the last quarter. Corient Private Wealth LLC acquired a new position in shares of Design Therapeutics during the fourth quarter worth about $253,000. XTX Topco Ltd increased its stake in shares of Design Therapeutics by 197.3% during the fourth quarter. XTX Topco Ltd now owns 35,284 shares of the company’s stock worth $331,000 after acquiring an additional 23,416 shares during the period. Finally, Millennium Management LLC lifted its position in Design Therapeutics by 162.8% in the fourth quarter. Millennium Management LLC now owns 180,866 shares of the company’s stock valued at $1,697,000 after purchasing an additional 112,043 shares during the period. 56.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DSGN has been the subject of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Design Therapeutics in a research note on Wednesday, January 21st. Royal Bank Of Canada raised Design Therapeutics from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $6.00 to $13.00 in a research report on Thursday, November 20th. Craig Hallum began coverage on Design Therapeutics in a research report on Wednesday, December 3rd. They set a “buy” rating and a $15.00 price target on the stock. Wall Street Zen upgraded Design Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Oppenheimer started coverage on shares of Design Therapeutics in a research report on Wednesday, January 7th. They set an “outperform” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $15.00.

About Design Therapeutics

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.